Literature DB >> 24019133

Yield of the second surveillance colonoscopy based on the results of the index and first surveillance colonoscopies.

Michael Samuel Morelli1, Elizabeth A Glowinski, Ravi Juluri, Cynthia S Johnson, Thomas F Imperiale.   

Abstract

BACKGROUND AND STUDY AIMS: The risk of advanced colorectal neoplasia (ACN) after the first surveillance colonoscopy is not well quantified. The aim of the current study was to quantify the risk of ACN on the second surveillance colonoscopy based on previous colonoscopic findings. PATIENTS AND METHODS: This was a single-site study of patients with index adenomas who underwent two surveillance colonoscopies. ACN was defined as advanced adenoma (≥ 1 cm, villous histology, or high-grade dysplasia) or as "high-risk" findings (advanced adenoma or ≥ 3 non-advanced adenoma [NAA]).
RESULTS: Among 509 patients with low-risk index findings, 61 (12.0 %; 95 % confidence interval [CI], 9.3 % - 15.1 %) had high-risk findings on the first surveillance colonoscopy, 11 of whom (18.0 %; 95 %CI 9.4 % - 30.0 %) had high-risk findings on second surveillance colonoscopy compared with 39 (8.7 %; 95 %CI 6.3 % - 11.7 %) of the remaining 448 patients who had normal or low-risk findings on the first surveillance colonoscopy (relative risk [RR] = 2.07; 95 %CI 1.12 - 3.83). Among 456 patients with high-risk index findings, 91 (20.0 %; 95 %CI 16.3 % - 23.9 %) had high-risk findings on the first surveillance colonoscopy, 20 of whom (22.0 %; 95 %CI 14.0 % - 31.9 %) had high-risk findings on second surveillance colonoscopy compared with 40 (11.0 %; 95 %CI 8.0 % - 146 %) of the remaining 365 patients who had normal or low-risk findings on first surveillance colonoscopy (RR = 2.01; 95 %CI 1.04 - 3.32). Results were similar when only advanced adenomas were considered.
CONCLUSIONS: Patients with high-risk findings on index and first surveillance colonoscopies require close surveillance. Those with low-risk findings on index colonoscopy and normal/non-advanced findings on the first surveillance colonoscopy have low subsequent risk of ACN. These and previous data may be useful for generating recommendations for the timing of the second surveillance colonoscopy. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2013        PMID: 24019133     DOI: 10.1055/s-0033-1344582

Source DB:  PubMed          Journal:  Endoscopy        ISSN: 0013-726X            Impact factor:   10.093


  10 in total

1.  Probability of high-risk colorectal neoplasm recurrence based on the results of two previous colonoscopies.

Authors:  Hye Won Park; Seungbong Han; Ji Young Lee; Hye-Sook Chang; Jaewon Choe; Yunsik Choi; Hoonsub So; Dong-Hoon Yang; Seung-Jae Myung; Suk-Kyun Yang; Jin-Ho Kim; Jeong-Sik Byeon
Journal:  Dig Dis Sci       Date:  2014-08-24       Impact factor: 3.199

2.  Does Colon Polyp Surveillance Improve Patient Outcomes?

Authors:  David Lieberman; Samir Gupta
Journal:  Gastroenterology       Date:  2019-10-12       Impact factor: 22.682

3.  Risk of Advanced Neoplasia Using the National Cancer Institute's Colorectal Cancer Risk Assessment Tool.

Authors:  Thomas F Imperiale; Menggang Yu; Patrick O Monahan; Timothy E Stump; Rebeka Tabbey; Elizabeth Glowinski; David F Ransohoff
Journal:  J Natl Cancer Inst       Date:  2016-08-31       Impact factor: 13.506

4.  Prevalence of advanced colorectal neoplasm after kidney transplantation: surveillance based on the results of screening colonoscopy.

Authors:  Jee Hye Kwon; Seong-Joon Koh; Ji Yeon Kim; Ji Won Kim; Kook Lae Lee; Byeong Gwan Kim; Jong Pil Im; Joo Sung Kim
Journal:  Dig Dis Sci       Date:  2015-01-11       Impact factor: 3.199

5.  Recommendations for Follow-Up After Colonoscopy and Polypectomy: A Consensus Update by the US Multi-Society Task Force on Colorectal Cancer.

Authors:  Samir Gupta; David Lieberman; Joseph C Anderson; Carol A Burke; Jason A Dominitz; Tonya Kaltenbach; Douglas J Robertson; Aasma Shaukat; Sapna Syngal; Douglas K Rex
Journal:  Gastroenterology       Date:  2020-02-07       Impact factor: 22.682

6.  Recommendations for Follow-Up After Colonoscopy and Polypectomy: A Consensus Update by the US Multi-Society Task Force on Colorectal Cancer.

Authors:  Samir Gupta; David Lieberman; Joseph C Anderson; Carol A Burke; Jason A Dominitz; Tonya Kaltenbach; Douglas J Robertson; Aasma Shaukat; Sapna Syngal; Douglas K Rex
Journal:  Gastrointest Endosc       Date:  2020-02-07       Impact factor: 9.427

7.  British Society of Gastroenterology/Association of Coloproctology of Great Britain and Ireland/Public Health England post-polypectomy and post-colorectal cancer resection surveillance guidelines.

Authors:  Matthew D Rutter; James East; Colin J Rees; Neil Cripps; James Docherty; Sunil Dolwani; Philip V Kaye; Kevin J Monahan; Marco R Novelli; Andrew Plumb; Brian P Saunders; Siwan Thomas-Gibson; Damian J M Tolan; Sophie Whyte; Stewart Bonnington; Alison Scope; Ruth Wong; Barbara Hibbert; John Marsh; Billie Moores; Amanda Cross; Linda Sharp
Journal:  Gut       Date:  2019-11-27       Impact factor: 31.793

8.  Recommendations for Follow-Up After Colonoscopy and Polypectomy: A Consensus Update by the US Multi-Society Task Force on Colorectal Cancer.

Authors:  Samir Gupta; David Lieberman; Joseph C Anderson; Carol A Burke; Jason A Dominitz; Tonya Kaltenbach; Douglas J Robertson; Aasma Shaukat; Sapna Syngal; Douglas K Rex
Journal:  Am J Gastroenterol       Date:  2020-03       Impact factor: 12.045

9.  Predicting the risk of recurrent adenoma and incident colorectal cancer based on findings of the baseline colonoscopy.

Authors:  Kimberly J Fairley; Jinhong Li; Michael Komar; Nancy Steigerwalt; Porat Erlich
Journal:  Clin Transl Gastroenterol       Date:  2014-12-04       Impact factor: 4.488

10.  Risk stratification for advanced colorectal neoplasia based on the findings of the index and first surveillance colonoscopies.

Authors:  Munenori Honda; Hideaki Naoe; Ryosuke Gushima; Hideaki Miyamoto; Masakuni Tateyama; Kouichi Sakurai; Yasushi Oda; Yoshitaka Murakami; Yasuhito Tanaka
Journal:  PLoS One       Date:  2021-01-22       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.